Published in J Mol Med (Berl) on March 12, 2010
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol (2012) 1.23
Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15
Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol (2011) 1.00
Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res (2013) 0.98
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther (2014) 0.93
Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation. Expert Opin Biol Ther (2011) 0.89
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol (2012) 0.85
The role of regulatory T cells in cancer immunology. Immunotargets Ther (2015) 0.82
Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron (2014) 0.80
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother (2011) 0.79
Heat shock proteins and regulatory T cells. Autoimmune Dis (2013) 0.77
Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection? Front Immunol (2017) 0.75
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 6.22
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 6.03
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97
Control of regulatory T cell lineage commitment and maintenance. Immunity (2009) 4.63
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol (2005) 3.95
Life and death in peripheral T cells. Nat Rev Immunol (2007) 3.67
Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med (2002) 3.49
Natural regulatory T cells: mechanisms of suppression. Trends Mol Med (2007) 3.37
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity (2007) 3.33
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol (2006) 3.28
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity (1998) 3.03
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest (2003) 2.33
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Interleukin-2 in the development and control of inflammatory disease. Immunol Rev (2008) 1.83
Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol (2003) 1.67
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46
Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol (2001) 1.25
Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol (2005) 1.18
Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol (2008) 1.14
Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother (2003) 1.01
Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett (2004) 0.99
Purification of natural killer cell cytotoxic granules for assaying target cell apoptosis. J Immunol Methods (2003) 0.95
Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. Clin Immunol (2005) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res (2005) 2.97
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem (2002) 2.10
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem (2006) 1.94
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res (2006) 1.91
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem (2008) 1.84
Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy (2010) 1.79
Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol (2009) 1.79
T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res (2003) 1.79
Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res (2005) 1.73
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods (2009) 1.69
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res (2007) 1.61
Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A (2005) 1.57
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods (2012) 1.46
Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res (2002) 1.45
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res (2006) 1.45
Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother (2003) 1.40
Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res (2007) 1.40
Comment on M. Guillot-Delost et al. (2008;10:834-846): Clinical-grade preparation of human natural regulatory T cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med (2009) 1.39
Bid-cardiolipin interaction at mitochondrial contact site contributes to mitochondrial cristae reorganization and cytochrome C release. Mol Biol Cell (2004) 1.38
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica (2011) 1.37
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res (2009) 1.37
Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res (2004) 1.32
Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One (2010) 1.32
Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother (2007) 1.30
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol (2002) 1.28
Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res (2005) 1.27
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother (2005) 1.25
Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck (2009) 1.25
Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother (2005) 1.25
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol (2008) 1.25
Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res (2002) 1.24
Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem (2004) 1.23
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol (2007) 1.22
Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol (2012) 1.21
Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer (2011) 1.17
Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol (2002) 1.17
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol (2003) 1.16
Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods (2011) 1.15
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med (2007) 1.15
Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology (2008) 1.15
Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother (2008) 1.14
Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol (2003) 1.14
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Tumor microenvironment and immune escape. Surg Oncol Clin N Am (2007) 1.12
Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem (2005) 1.11
Functional linkage between NOXA and Bim in mitochondrial apoptotic events. J Biol Chem (2007) 1.10
Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol (2008) 1.10
Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res (2002) 1.09
Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol (2002) 1.09
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res (2013) 1.08
T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer (2006) 1.07
Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer (2006) 1.07
Exosomes and tumor-mediated immune suppression. J Clin Invest (2016) 1.06
Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer (2007) 1.05
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother (2011) 1.04
Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck (2007) 1.04
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol (2004) 1.03